Clinical Cardiology Alert – June 1, 2022
June 1, 2022
View Issues
-
Oral Anticoagulation Falls Short as Default Treatment Post-TAVR
In patients without an indication for anticoagulation undergoing transcatheter aortic valve replacement, treatment with edoxaban did not significantly affect the incidence of leaflet thrombosis as detected by CT scans.
-
Sodium Restriction in Chronic, Stable Heart Failure Patients
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
-
Outcomes of COVID-19-Associated Acute Myocarditis
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.
-
Anticoagulation Therapy in Octogenarians with Atrial Fibrillation
In patients age 80 years and older with atrial fibrillation who were not considered for oral anticoagulants because of serious comorbidities, one-quarter of the recommended daily dose of edoxaban was superior to placebo for preventing thromboembolic events.
-
Is the Canadian Syncope Risk Score Valid?
Researchers found the Canadian Syncope Risk Score accurately predicts which patients are low risk for discharge. However, since it is largely driven by the physician’s final risk classification at ED discharge, the score’s clinical utility is uncertain.